Salbutamol 2mg/tab 100 Tabletten by Sterling Knight Pharmaceuticals

Usage

1. Select your starting dose based on prior beta-2 agonist experience — users with no clenbuterol or formoterol history should begin at 2 mg once daily given salbutamol's different potency ceiling.
2. Take each dose with a full glass of water and a light meal to reduce gastric irritation; unlike long-acting class members, salbutamol's short window means missed doses can be skipped rather than doubled.
3. Schedule doses at least 6 hours apart and avoid any dose within 5 hours of sleep to prevent stimulant-related insomnia — a particular advantage over clenbuterol, which remains active overnight even when dosed in the morning.
4. When splitting 2 mg tablets for sub-threshold increments, use a calibrated pill cutter; HPLC-verified content uniformity means halved tablets reliably deliver approximately 1 mg rather than a variable fraction.
5. Monitor resting heart rate daily during the build-up phase; because salbutamol's beta-2 selectivity is higher than clenbuterol's, sustained resting HR above 90 bpm warrants dose reduction rather than discontinuation in most cases.
6. Apply the 2-weeks-on / 2-weeks-off cycle structure to preserve receptor sensitivity — the same receptor-downregulation dynamic that applies to all beta-2 agonists in the class, but more easily managed with salbutamol's 4–6 h clearance.

Warnings

Frequently asked questions

How does salbutamol compare to clenbuterol in terms of half-life and dosing flexibility?

Salbutamol carries an oral half-life of approximately 4–6 hours, compared to clenbuterol's 36–48 hours. This shorter window means salbutamol clears the system within a single day, allowing users to adjust dosing day-to-day without compounding accumulation. Clenbuterol's prolonged half-life offers less flexibility once a dose is administered, making salbutamol the preferred choice when precise daily titration is required.

Is salbutamol or clenbuterol more selective for beta-2 receptors, and why does it matter?

Salbutamol maintains stronger beta-2 receptor selectivity at performance-range doses compared to clenbuterol, which exhibits measurable beta-1 spillover at higher doses. Beta-1 activation is the primary driver of clenbuterol-associated cardiovascular stress. For users sensitive to heart-rate elevation or arrhythmia risk, salbutamol's superior selectivity profile makes it the more appropriate class member, particularly during initial dose-finding phases.

Where does formoterol sit in the beta-2 agonist class relative to salbutamol?

Formoterol is a long-acting beta-2 agonist (LABA) with an 8–12 hour duration of action, positioning it between salbutamol (short-acting, 4–6 h) and clenbuterol (ultra-long, 36–48 h). Formoterol also exhibits higher intrinsic efficacy at the receptor than salbutamol. In practical terms, formoterol offers sustained activity but reduces the user's ability to make intra-day dose corrections — a trade-off that salbutamol's format avoids.

Why does the 2mg per tablet concentration matter for titration compared to other salbutamol products?

Sterling Knight's 2 mg/tab is the lowest single-tablet concentration in this product group. Lower per-tablet dosing allows users to build up incrementally — starting at 2 mg per dose — without committing to higher fixed-dose tablets that cannot be accurately split. Scored tablets at this concentration permit quarter- and half-tablet increments, giving a practical dose range of approximately 2–16 mg/day in fine steps before any splitting is required.

Can Sterling Knight Salbutamol 2mg tablets be split or adjusted mid-cycle, and what does the tablet format allow?

Yes. The 2 mg tablet format is specifically suited to mid-cycle dose adjustment. Because each unit contains only 2 mg of active ingredient — verified by HPLC content-uniformity testing — splitting a tablet delivers a predictable 1 mg fraction rather than an approximation. This is particularly relevant during the final days of a salbutamol phase, where dose tapering minimises rebound effects without requiring a separate lower-strength product. (2) angle_used

Manufacturer

Sterling Knight Pharmaceuticals' approach to its Salbutamol 2 mg/tab product reflects a specific portfolio consideration: within a catalogue that spans multiple beta-2 agonist concentrations and compound classes, the lowest-concentration tablet in any given product line demands the strictest per-unit mass accuracy, because fractional dosing errors that are clinically negligible at 20 mcg or 40 mcg clenbuterol equivalents become proportionally significant when the declared active load is only 2 mg. To address this, Sterling Knight applies a validated tablet compression and granulation process calibrated specifically to low-mass API distribution, ensuring that active ingredient migration across the tablet matrix during storage does not produce end-to-end potency variance within the blister strip. Finished tablets from each production batch are subject to HPLC content-uniformity testing against certified salbutamol sulphate reference standards — a step that validates both the declared 2 mg load and the batch-to-batch consistency on which multi-week titration protocols depend. The entire production workflow is executed within GMP-certified facility conditions, with environmental and equipment-qualification records maintained in line with pharmaceutical manufacturing standards applicable to solid oral dosage forms.